Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.

[1]  Yichao Wang,et al.  MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A/PGRN axis to prevent the epithelial-mesenchymal transition , 2021, Molecular Biology Reports.

[2]  J. Hua,et al.  Mir-34c affects the proliferation and pluripotency of porcine induced pluripotent stem cell (piPSC)-like cells by targeting c-Myc. , 2021, Cells & development.

[3]  Rui Luo,et al.  miR-34c Targets MET to Improve the Anti-Tumor Effect of Cisplatin on Ovarian Cancer , 2020, OncoTargets and therapy.

[4]  B. Baradaran,et al.  Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy , 2020, Journal of cellular physiology.

[5]  L. McDonnell,et al.  ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer , 2019, Front. Oncol..

[6]  M. Piccart,et al.  Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial , 2019, Clinical Cancer Research.

[7]  Z. Rezaei,et al.  Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance. , 2019, DNA and cell biology.

[8]  J. Zhang,et al.  Targeted regulation of miR-195 on MAP2K1 for suppressing ADM drug resistance in prostate cancer cells. , 2018, European review for medical and pharmacological sciences.

[9]  Junjiang Fu,et al.  MicroRNA-34 family in breast cancer: from research to therapeutic potential , 2018, Journal of Cancer.

[10]  H. Elghazaly,et al.  MicroRNA‐21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2‐positive metastatic breast cancer , 2018, Journal of cellular biochemistry.

[11]  M. Ghaedi,et al.  Sonochemical incorporated of cytosine in Cu-H2bpdc as an antibacterial agent against standard and clinical strains of Proteus mirabilis with rsbA gene. , 2018, Ultrasonics sonochemistry.

[12]  Yun-jie He,et al.  Functional miRNAs in breast cancer drug resistance , 2018, OncoTargets and therapy.

[13]  Jin-hai Tang,et al.  Exosomal MicroRNA MiR-1246 Promotes Cell Proliferation, Invasion and Drug Resistance by Targeting CCNG2 in Breast Cancer , 2017, Cellular Physiology and Biochemistry.

[14]  Hsien-Da Huang,et al.  miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions , 2017, Nucleic Acids Res..

[15]  Adnan Khan,et al.  Clinicopathological features associated to MiRNA-195 expression in patients with breast cancer: Evidence of a potential biomarker , 2017, Pakistan journal of medical sciences.

[16]  Yujie Liu,et al.  MiR-195 Inhibits Tumor Growth and Metastasis in Papillary Thyroid Carcinoma Cell Lines by Targeting CCND1 and FGF2 , 2017, International journal of endocrinology.

[17]  A. Guerrero-Zotano,et al.  PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment , 2016, Cancer and Metastasis Reviews.

[18]  Bao Zhang,et al.  Integrated analysis of microRNA regulatory network in nasopharyngeal carcinoma with deep sequencing , 2016, Journal of Experimental & Clinical Cancer Research.

[19]  E. Giovannetti,et al.  MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients , 2015, Oncotarget.

[20]  Gary D Bader,et al.  Pathway and network analysis of cancer genomes , 2015, Nature Methods.

[21]  Wenjin Xi,et al.  MiR‐200c suppresses TGF‐β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer , 2014, International journal of cancer.

[22]  Lei Wang,et al.  MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN , 2014, BMB reports.

[23]  A. Yang,et al.  Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R , 2014, BMC Cancer.

[24]  J. Cai,et al.  Association of cyclin D1 and survivin expression with sensitivity to radiotherapy in patients with nasopharyngeal carcinoma. , 2014, Genetics and molecular research : GMR.

[25]  R. Dahiya,et al.  Inhibition of PTEN Gene Expression by Oncogenic miR-23b-3p in Renal Cancer , 2012, PloS one.

[26]  R. Subramanian,et al.  Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells. , 2012, International journal of oncology.

[27]  R. Bast,et al.  Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients , 2012, Cancer.

[28]  W. Muller,et al.  HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. , 2012, Cancer research.

[29]  Hui Zhou,et al.  MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. , 2012, Neuro-oncology.

[30]  Yongsheng Song,et al.  MicroRNA‐195‐5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression , 2012, FEBS letters.

[31]  S. Hilsenbeck,et al.  Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation , 2011, Breast Cancer Research.

[32]  Chang Gong,et al.  Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer* , 2011, The Journal of Biological Chemistry.

[33]  Christian Asseburg,et al.  Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial , 2011, Acta oncologica.

[34]  Bing-Hua Jiang,et al.  Analysis of MiR-195 and MiR-497 Expression, Regulation and Role in Breast Cancer , 2011, Clinical Cancer Research.

[35]  Yun Xiao,et al.  MiRNA–miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features , 2010, Nucleic acids research.

[36]  Ming Mao,et al.  Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. , 2010, International journal of molecular medicine.

[37]  J. Diehl,et al.  Nuclear cyclin D1: An oncogenic driver in human cancer , 2009, Journal of cellular physiology.

[38]  N. Hynes,et al.  ErbB receptors and signaling pathways in cancer. , 2009, Current opinion in cell biology.

[39]  M. Bergström,et al.  Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. , 2009, Nuclear medicine and biology.

[40]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[41]  John W M Martens,et al.  Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer , 2008, Proceedings of the National Academy of Sciences.

[42]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[43]  Carme Camps,et al.  hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer , 2008, Clinical Cancer Research.

[44]  G. Tzivion,et al.  Raf kinases: function, regulation and role in human cancer. , 2007, Biochimica et biophysica acta.

[45]  R. Nahta,et al.  HER2 therapy: Molecular mechanisms of trastuzumab resistance , 2006, Breast Cancer Research.

[46]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[47]  R. Murali,et al.  Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-Activation. , 2016, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[48]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[49]  Hansjuerg Alder,et al.  The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. , 2009, Gynecologic oncology.

[50]  J. Tostain,et al.  Elevated serum-circulating RNA in patients with conventional renal cell cancer. , 2008, Anticancer research.